Mazdima

Ceftazidime

Mazdima

Active substance

Ceftazidime

Strenght and pharmaceutical forms

500 mg/1,5 ml powder and solvent for injectable solution for im use
1 g/3 ml powder and solvent for injectable solution for im use

ATC

J01DD02 - Antibacterial for systemic use. Third Generation Cephalosporins

Therapeutic Indications

Panzid is indicated for the treatment of infections listed below in adults and in children including babies (from birth).

Nosocomial pneumonia
Bronchopulmonary infections in cystic fibrosis
Bacterial meningitis
Chronic suppurative media otitis
Outside malignant otitis
Complicated urinary tract infections
Complicated skin and soft tissue infections
Intra-abdominal complications
Infections of the bones and joints
Peritonitis associated with dialysis in patients with continuous peritoneal dialysis (Continuous ambulatory peritoneal dialysis-CAPD).
Treatment of patients with bacteremia that occurs or is suspected to be associated with one of the infections listed above.
Ceftazidime can be used in the management of neutropenic patients with fever suspected to be caused by a bacterial infection.

Ceftazidime can be used in peri-operative prophylaxis of urinary tract infections of patients undergoing trans urethral resection of the prostate (TURP).

Marketing Authorization Holder

Magis Farmaceutici S.r.l.


Products of the same therapeutic areas

Events

13-14/09/2019

SCLEROTHERAPY & VENOUS ABLATION

Pisa Palazzo dei Congressi

Primo congresso intersocietario Associazione Flebologica Italiana, Società Italiana FleboLinfologica, Società Italiana di Flebologia Clinica e Sperimentale

 Download

14-16/06/2019

33° Congresso Nazionale della Società Italiana per lo Studio delle Cefalee

Napoli

Congresso Nazionale della Società Italiana per lo Studio delle Cefalee